脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)等多因子檢測試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Phospholipase A2 Group VII (LpPLA2) ,etc. by FLIA (Flow Luminescence Immunoassay)
PLA2G7; PAF-AH; PAFAH; Lp-PLA2; LDL-PLA2; Platelet Activating Factor Acetylhydrolase,Plasma; Phospholipase A2,Group VII; LDL-associated phospholipase A2; Phospholipase A2, Lipoprotein Associated
（注：單次混測多因子不超過8個(gè)指標(biāo) ）
- 編號(hào)LMA867Hu
- 物種Homo sapiens (Human，人)相同的名稱，不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長3.5h
- 檢測范圍0.04-40ng/mL
- 靈敏度最小可檢測劑量小于等于0.013 ng/mL.
- 樣本類型Serum, plasma and other biological fluids
- 下載英文說明書 中文說明書
- 規(guī)格8指標(biāo)數(shù)7指標(biāo)數(shù)6指標(biāo)數(shù)5指標(biāo)數(shù)4指標(biāo)數(shù)3指標(biāo)數(shù)2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格¥ 2359¥ 2449¥ 2586¥ 2767¥ 2948¥ 3221¥ 3629¥ 4536 添加到價(jià)格計(jì)算器 計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
本試劑盒用于檢測脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)等多因子檢測試劑盒(流式熒光發(fā)光法)，經(jīng)檢測與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制，不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測，因此本試劑盒有可能與未經(jīng)檢測的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)等多因子檢測試劑盒(流式熒光發(fā)光法)（加標(biāo)樣品），重復(fù)測定并計(jì)算其均值，回收率為測定值與理論值的比率。
| 樣本 | 回收率范圍(%) | 平均回收率(%) |
| serum(n=5) | 92-99 | 96 |
| EDTA plasma(n=5) | 81-102 | 97 |
| heparin plasma(n=5) | 90-101 | 96 |
精密度
精密度用樣品測定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差：取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測,每份樣本連續(xù)測定20 次，分別計(jì)算不同濃度樣本的平均值及SD值。
批間差：選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測定，每個(gè)樣本使用同一試劑盒重復(fù)測定8次，分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差： CV<10%
批間差： CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)等多因子檢測試劑盒(流式熒光發(fā)光法)，并倍比稀釋成1:2，1:4，1:8，1:16的待測樣本，線性范圍即為稀釋后樣本中脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)等多因子檢測試劑盒(流式熒光發(fā)光法)含量的測定值與理論值的比率。
| 樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 93-101% | 97-105% | 95-102% | 94-101% |
| EDTA plasma(n=5) | 95-103% | 96-103% | 87-94% | 89-97% |
| heparin plasma(n=5) | 98-105% | 98-105% | 82-103% | 91-98% |
穩(wěn)定性
經(jīng)測定，試劑盒在有效期內(nèi)按推薦溫度保存，其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測值的影響，實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致，尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備；
2. 加樣（標(biāo)準(zhǔn)品、樣本、磁珠）標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL，
37°C酶標(biāo)板振蕩器孵育90分鐘；
3. 磁吸甩干，加檢測溶液A100μL，37°C酶標(biāo)板振蕩器孵育60分鐘；
4. 磁吸洗板3次；
5. 加檢測溶液B100μL，37°C振動(dòng)孵育30分鐘；
6. 磁吸洗板3次；
7. 加鞘液100μL，旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體包被于磁珠，制成固相載體，向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠，其中的脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)等多因子檢測試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合，然后加入生物素化的脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)等多因子檢測試劑盒(流式熒光發(fā)光法)抗體，將未結(jié)合的生物素化抗體洗凈后，加入PE標(biāo)記的親和素，再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)等多因子檢測試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPA867Hu02 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA867Hu03 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA867Hu04 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA867Hu01 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA867Hu01 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA867Hu01 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA867Hu81 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| LAA867Hu71 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| MAA867Hu21 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA867Hu22 | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)單克隆抗體 | WB; IHC; ICC; IP. |
| SEA867Hu | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCA867Hu | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)檢測試劑盒(化學(xué)發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMA867Hu | 脂蛋白關(guān)聯(lián)磷脂酶A2(LpPLA2)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Science & Sports | The effects of different intensity walking programs on serum blood lipids, high-sensitive C-reactive protein, and lipoprotein-associated phospholipase A2 in premenopausal women[ScienceDirect: S0765159710000262] |
| Metabolic Syndrome and Related Disorders | Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease[Wiley: source] |
| 34 | Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study[PubMed: 22240497] |
| PLoS ONE | Effects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex Vivo[PubMed: PMC3759413] |
| China Pharmacy | Influence of Tongfengtai Granules on Inflammatory Factor in Acute Gouty Arthritis Model Rats[Source] |
| Atherosclerosis | Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients.[Pubmed: 23958269] |
| Journal of Diabetes Research | Lipoprotein-Associated Phospholipase A2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus[Hindawi: 278063] |
| Health | The Role of Asymmetric Dimethylarginine and Lipoprotein Associated Phospholipase A2 in Children and Adolescents with Dyslipidemia[Scirp:Source] |
| Biology Bulletin | In vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human blood[Springer:Source] |
| Gynecol Endocrinol. | Lipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus.[Pubmed:24397392] |
| Journal of Diabetes Research | Lipoprotein-Associated Phospholipase A 2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus[Pubmed:24818163] |
| Metabolism. | Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes[Pubmed:25034387] |
| J Am Heart Assoc | Effect of Extended‐Release Niacin on High‐Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin‐Treated Patients[PubMed: 26374297] |
| Czecho-Slovak Dermatology / Cesko-Slovenska Dermatologie | V[Ebscohost] |
| Endocrinol Metab (Seoul). | Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2?in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome[pmc:PMC4803547] |
| Clin Pharmacol Ther.? | Effect of dipyridamole on myocardial reperfusion injury: A double‐blind randomized controlled trial in patients undergoing elective coronary artery bypass surgery[Pubmed:25773594] |
| Lipids in Health and Disease | Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A 2 and secretory phospholipase A 2 in patients with newly …[articles:10.1186] |
| Acta Endocrinologica | SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA.[jrnl:1841098] |
| Biomarker for diagnosis of moyamoya disease[:] | |
| JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION | Circulating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventions[Pubmed: 32859455] |
| chinese neurosurgical journal | Can admission lipoprotein-associated phospholipase A2 predict the symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage?[] |